Quick ReadPlain-language overview · read this first
Amgen is a large biopharma company focused on rare and chronic diseases, with 2025 revenue of $36.75 billion, free cash flow of $8.1 billion, a current price of $331.57, and a rating of Watch.
The moat is on the narrow side: Prolia/XGEVA patents expired in 2025, ENBREL fell 33% year over year, and Otezla was brought by CMS into IRA price setting. The $27.8 billion Horizon acquisition raised the balance sheet, with goodwill plus intangibles over $40 billion, shareholders' equity of only $8.66 billion, and negative tangible net worth; debt reduction brought net debt/EBITDA back to 2.7x. Current P/E is about 23x and P/FCF about 22x, with the quality premium already fairly full.
Discounting $8.76 billion of Owner Earnings gives a fair value of $260-320, with an ideal buy of $240-280 (14-17x); above $380 is clearly overvalued. The worst case is not bankruptcy but long-term failure to compound, with a permanent drawdown of 35%-50%; a good company, but not a good price; wait for a thicker discount before stepping in.
LeadA high-quality but currently not-cheap mature biopharma asset; under a patent cliff, Medicare price cuts and a heavier balance sheet after the Horizon acquisition, the ~$331 price lacks a margin of safety, with an ideal buy range of $240-280. Rating: Watch.
Prices in the article are as of publication; see the valuation band above for the live price.
Conclusion First
Investment Rating: Watch
Core judgment: Amgen is a business I can understand: it generates ongoing cash flow through a portfolio of prescription drugs targeting serious, chronic, and rare diseases. In 2025 total revenue was $36.751 billion and product sales were $35.148 billion, of which 14 products had annual sales above $1 billion and 18 products set annual sales records, showing the company does not live off a single "miracle drug." At the same time, this is not a "collect money while you sleep" business: ENBREL is clearly declining, the core patents for Prolia/XGEVA expired in 2025, IRA drug-price negotiation and state-level price controls are eroding the pricing power of mature products, and the balance sheet has grown notably heavier after the Horizon acquisition. At roughly $331.57 near May 21, 2026, the market has priced in a good share of the "high quality + pipeline extending product life + deleveraging" expectations, but the margin of safety left for new buyers is not obvious. For an investment objective spanning 10-plus years with a balanced, conservative tilt, I would rather view it as a high-quality but currently not-cheap mature biopharma asset than as a meaningfully undervalued value investment.
Is there a margin of safety at the current price: not obvious Based on a current market cap of about $180.37 billion and year-end 2025 net debt of about $45.48 billion, Amgen's enterprise value is about $225.8 billion; this implies 2025 EV/EBITDA of about 13.4x, P/FCF of about 22.3x, and P/E of about 23.1x. For a mature large-cap drugmaker with high-quality cash flow that at the same time faces a patent cliff, Medicare price pressure, and post-merger integration tests, this set of multiples is closer to "reasonable-to-expensive" than to "clearly cheap." More importantly, on my conservative owner-earnings yield calculated below, it stands only modestly above the roughly 4.50% yield on the U.S. 10-year Treasury as of May 19, 2026; the risk compensation is not thick.
Suitable investor type: It is better suited to long-term value investors who want to hold a defensive healthcare leader in their portfolio, who value long-term cash flow and dividend discipline, but who are demanding about the entry price; it is less suited to those chasing it as a high-beta growth stock, and not suited to treating it as a "deeply undervalued, load-up" opportunity. Its greatest appeal lies in business resilience and cash flow, not in a cheap valuation.
Biggest uncertainties: First, the pace at which Prolia/XGEVA are eroded by biosimilars after patent expiry; second, the extent of profit decline for ENBREL/Otezla under IRA drug-price negotiation and state-level price controls; third, whether the Horizon acquisition can ultimately deliver long-term returns above the cost of capital, and whether follow-on pipeline assets such as MariTide can fill the gap left by aging products.
Scoring overview: Business understandability 4/5; industry attractiveness 3.5/5; moat strength 3.5/5; management and capital allocation 3/5. These scores correspond not to a "bad company" but to a "good company that, having entered maturity, must be judged more strictly on price and capital allocation."
Methodology note: Below I try to distinguish 【Fact】, 【Assumption】, 【Inference】, and 【Opinion】; the growth rates, discount rates, and maintenance capex involved in valuation are all 【Assumption】; ratios derived from financial data are 【Calculation】; the final rating is 【Opinion】.
Business Understanding and Industry Landscape
Core business, customers, and how it charges. 【Fact】Amgen operates as a single reportable segment, but its revenue essentially comes from a basket of prescription drugs plus a small amount of other revenue. The company discloses sales by product and geography; 2025 product sales were $35.148 billion and other revenue was $1.603 billion. The most important products in 2025 include Prolia $4.414 billion, Repatha $3.016 billion, ENBREL $2.226 billion, XGEVA $2.084 billion, EVENITY $2.100 billion, TEPEZZA $1.903 billion, BLINCYTO $1.559 billion, and KRYSTEXXA $1.340 billion. No single product accounts for more than 13% of product sales, which is markedly better than biotechs reliant on one product. The company essentially charges through sales during the patent/data-protection period of innovative and biologic drugs, rather than through one-off project fees.
Whether revenue is recurring, stable, and predictable. 【Fact】From 2021 to 2025 revenue grew from $25.979 billion to $36.751 billion, operating cash flow grew from $9.261 billion to $9.958 billion, free cash flow was positive for five consecutive years and higher than net income every year. In 2025 the company had 14 products with annual sales above $1 billion, meaning revenue sources are relatively diversified. In Q1 2026, management further emphasized in the earnings release that 16 brands achieved double-digit growth, indicating the company's near-term operating momentum remains intact. 【Inference】But this "stability" is more a portfolio-level stability than the stability of any single product; at large drugmakers, demand is not the problem, the product lifecycle is.
Cost structure and business transparency. 【Fact】In 2025 Amgen's cost structure was roughly: cost of sales 32.8% of total revenue, R&D 19.8%, SG&A 19.2%, operating margin about 24.7%; the official historical financials page shows FY2025 gross margin of about 70.78%. The company's business model is not complex at the "top layer" (R&D, approval, pricing, ramp-up, lifecycle management, patent expiry), but at the "bottom layer" it depends heavily on patents, legal affairs, government payment policy, manufacturing quality systems, and the clinical pipeline, making it a business that is easy to understand at the top and highly specialized underneath.
Key dependencies. 【Fact】Amgen clearly depends on three external conditions: first, patent and biologic regulatory barriers; second, the Medicare/government pricing environment, especially IRA and state-level drug-price constraints; third, the pace of pipeline replenishment, because the decline of older drugs is a certain event. In its 10-K the company explicitly states that Prolia/XGEVA are expected to see accelerated erosion after patent expiry in 2025; CMS has selected ENBREL and Otezla for Medicare price setting; Colorado's PDAB has even set a ceiling payment price below WAC for ENBREL, effective as early as 2027. In other words, this business lives not on the macro cycle but on regulation, patents, and R&D execution.
Would I hold it if the stock market closed for 5 years. 【Opinion】If the entry price were lower, I would. Amgen's business is real enough, its demand does not depend on economic prosperity, and its cash flow is fairly solid; but at the current price I am more accepting a "satisfactory return" than locking in a "high-conviction excess return." For a long-term business owner, this distinction matters.
Industry stage and competitive landscape. 【Fact】Amgen sits in the mature large-cap biopharma industry: demand persists over the long run, but the profit pool keeps shifting from patent-expired products to new products, and winners depend on compound execution across R&D, legal, manufacturing, and commercialization capabilities. The company's 2025 revenue grew 10%, but part of that came from the rare-disease portfolio after the Horizon acquisition. The 2024 earnings release noted that excluding Horizon, product sales still grew 7% year over year, showing it is not purely stacking revenue via M&A; at the same time, 2025 growth also relied heavily on stronger products such as Repatha, EVENITY, BLINCYTO, TEPEZZA, and KRYSTEXXA, while mature products such as ENBREL, XGEVA, and KYPROLIS have come under varying degrees of pressure.
Main competitors and industry-attractiveness assessment. 【Fact】Among capital-market comparables, Amgen currently trades at about 23.1x P/E; Bristol Myers about 16.4x, Regeneron about 15.9x, Merck about 31.8x, Eli Lilly about 36.2x, while AbbVie's current P/E is about 104.6x, but this figure is heavily affected by GAAP conventions and accounting noise and cannot be mechanically compared across peers. 【Opinion】This shows that in the market's eyes Amgen is neither a high-growth star like Lilly nor as clearly discounted as BMS/REGN; it occupies the middle ground of a "mature, high-quality large drugmaker." The industry itself is a good one, but because the patent cliff and regulatory price pressure persist, I give industry attractiveness 3.5/5, defined as: a good industry, but not an easy one; good companies can make big money, and poor execution is punished quickly.
Moat and Management
Moat, assessed item by item. 【Opinion】Amgen's moat exists, but is not boundless. Brand advantage: moderate. It is not a consumer brand, but among physicians, hospitals, payers, and patients, the quality, safety, and supply reliability of biologics carry real weight; in its 10-K Amgen also explicitly states that patients, physicians, and payers still value its product reputation, supply reliability, and safety.
Cost advantage: moderate. The company has both innovative-drug and biosimilar experience, and by 2025 it had a history of 8 biosimilars launched, showing that its manufacturing, registration, legal, and commercialization systems have economies of scale. But the problem is that a drugmaker's cost advantage is usually insufficient to offset the price collapse after patent expiry, so this is not the absolute "bigger is cheaper" moat of the consumer-goods industry.
Scale advantage: moderate-to-strong. 14 products with annual sales above $1 billion, a global sales network, steady R&D investment, and a manufacturing platform are themselves scale barriers that are extremely hard to replicate. In 2025 R&D reached $7.272 billion, of which late-stage clinical programs took $4.281 billion, showing it still has the ability to keep "loading ammunition" for the next round of product turnover.
Network effects: weak. Amgen has almost no typical internet-style network effects.
Switching costs: moderate. For life-science products, patients, physicians, hospitals, and payers have some inertia in clinical pathways, reimbursement, and supply chains, but the 10-K also repeatedly warns that once multiple biosimilars or generics launch, competition intensifies quickly, showing that switching costs are not unbreakable.
Channel advantage: moderate. Amgen clearly has strong PBM/payer negotiating power on some products, and it has even drawn an antitrust complaint from Regeneron over its contracting strategy for Repatha, ENBREL, and Otezla, which indirectly shows its channel and bundled-negotiation capability is not weak; but this kind of advantage is more a commercialization capability than a permanent monopoly.
Patents, licenses, regulatory barriers: strong but time-limited. This is Amgen's most core moat. However, 2025 happens to be a watershed: the key patents for Prolia/XGEVA have expired, and the company itself expects accelerated erosion in 2026; ENBREL and Otezla will also be affected by IRA price setting. In other words, the barrier is deep, but it expires, and policy may weaken its economic value ahead of schedule.
Data advantage: uncertain. The company of course holds clinical and real-world data in R&D, but the public materials I found this time are insufficient to treat "data" as an independent, quantifiable, sustainable core moat, so I say "uncertain" rather than assert it exists. Corporate culture and operating capability: moderate-to-strong. Multiple products set record sales in 2025, and the company continued to increase late-stage clinical investment while deleveraging, showing the organization did not stall out because of the large acquisition.
Is the moat widening, stable, or narrowing. 【Opinion】My judgment: stable-to-narrowing overall. Growth brands and the rare-disease portfolio keep the moat from collapsing, but the Prolia/XGEVA patent expiry, ENBREL price pressure, and IRA spread mean the "old moat" is narrowing, while the "new moat" must be filled by Repatha, EVENITY, TEPEZZA, KRYSTEXXA, BLINCYTO, TEZSPIRE, and the follow-on pipeline. The market currently takes a relatively optimistic view of this.
Inflation, recession, and the sustainability of high margins. 【Fact】In 2025 TEPEZZA's growth came mainly from higher net selling prices, but several mature products such as ENBREL, Repatha, and Prolia/XGEVA either already saw net-price declines or management has guided that price pressure will continue in 2026. 【Opinion】Therefore, in an inflationary environment Amgen has only selective pricing power: strong for rare-disease and highly differentiated new products, weak for mature Medicare products. As for recession, disease demand itself is fairly insensitive to GDP, and the company maintained positive net income, operating cash flow, and free cash flow every year from 2021 to 2025, so I believe it will most likely remain profitable in a downturn; its bigger enemy is not recession but the patent cliff and policy.
Moat strength score: 3.5/5. This is a real moat, but by no means one that "only widens, never narrows." For a competitor to replicate Amgen's product portfolio, manufacturing system, and global commercialization capability typically takes many years and vast capital; but to replicate the profit pool of a mature product whose patent has peaked and that has been repriced by payers, the pace can be much faster.
Whether management is trustworthy. 【Fact】Robert A. Bradway has been CEO since 2012 and chairman since 2013; the 2026 proxy statement shows that 2025 Say-on-Pay won 94% shareholder support, and management and the board held governance discussions after the annual meeting with shareholders holding about 59% of shares outstanding. On equity, the CEO's stock-ownership requirement is 6x annual salary, and all applicable executives met the ownership requirement in 2025; as an NEO, Bradway holds about 1.472 million common shares and has about 862,000 shares of interests obtainable within 60 days. 【Opinion】This is enough to show management is not a "salary-but-no-stock" professional manager, but it does not amount to founder-style ultra-high alignment either.
Whether capital allocation is rational. 【Fact】In 2025 the company did essentially no open-market buybacks; in 2024 it repurchased only about $200 million; instead, in 2024 and 2025 the company retired $4.5 billion and $6.0 billion of debt respectively, while continuing to raise the dividend, which rose to $2.52 per share in Q1 2026. The Horizon acquisition closed in October 2023 at total consideration of about $27.8 billion, and 2023 debt leverage rose to 4.4x; but by year-end 2025 the company had cash of $9.129 billion, long-term debt of $50.005 billion, and shareholders' equity of $8.658 billion, with leverage already falling back.
My assessment of capital allocation. 【Opinion】I give 3/5, for one plus and one minus. The positive: after the acquisition, management did not keep doing large-scale buybacks to "beautify EPS," but prioritized cutting debt, protecting the dividend, and protecting R&D, which is a plus for conservative-leaning shareholders. The negative: the $27.8 billion Horizon acquisition itself raised balance-sheet risk and added intangible-asset and amortization burdens, and its long-term IRR has yet to be fully proven. TEPEZZA and KRYSTEXXA sold well in 2025, showing this acquisition is not a bad asset; but whether it is "excellent capital allocation" or "reasonable capital allocation still to be proven," I do not think a conclusion can be drawn lightly.
One point that deserves special mention. 【Fact】In the design of the 2026-2028 long-term incentives, the company changed the non-GAAP ROIC target to a relative TSR target, and moved relative TSR from a modifier to one of the formal performance goals. 【Opinion】From the perspective of a long-term business owner, this is not my favorite change: constraining management with return on capital is usually closer to intrinsic value creation than using relative share-price performance. This is not a red flag, but it is at least a yellow one.
Financial Quality and Owner Earnings
Overview of the past five years of financial quality. The table below summarizes what I consider the most critical 2021-2025 financial metrics. The raw revenue, profit, cash-flow, and balance-sheet data come from Amgen's official historical financials page, the 2025 10-K, and the full-year earnings releases for 2021-2024; the FCF conversion rate, ROIC, net debt/EBITDA, and interest coverage in the table are 【Calculation】 derived from these, not company-disclosed figures.
| Year | Revenue ($B) | Operating margin | Net income ($B) | Operating cash flow ($B) | Free cash flow ($B) | FCF/net income | Est. ROIC | Net debt/EBITDA | Interest coverage |
|---|---|---|---|---|---|---|---|---|---|
| 2021 | 25.98 | 29.4% | 5.89 | 9.26 | 8.38 | 1.42x | ~21.0% | ~2.3x | To be added |
| 2022 | 26.32 | 36.3% | 6.55 | 9.72 | 8.79 | 1.34x | ~26.1% | ~2.4x | ~6.8x |
| 2023 | 28.19 | 28.0% | 6.72 | 8.47 | 7.36 | 1.10x | ~14.5% | ~3.6x | ~2.7x |
| 2024 | 33.42 | 21.7% | 4.09 | 11.49 | 10.39 | 2.54x | ~11.3% | ~3.6x | ~2.3x |
| 2025 | 36.75 | 24.7% | 7.71 | 9.96 | 8.10 | 1.05x | ~14.4% | ~2.7x | ~3.3x |
Reading the table. 【Fact】Revenue is strengthening, but margins are not improving linearly. Operating margin spiked above 36% in 2022, was dragged down in 2023-2024 by the amortization, integration, and interest burden after the Horizon acquisition, and recovered to 24.7% in 2025. Looking only at GAAP profit, one might misjudge that the company "suddenly deteriorated" in 2024; but 2024 operating cash flow of $11.49 billion and free cash flow of $10.39 billion show the cash machine did not fail; the distortion came mostly from accounting and merger amortization. For value investors, this is a company whose cash flow is more trustworthy than net income.
The authenticity of profits and their cash content. 【Fact】From 2021 to 2025 Amgen's free cash flow was higher than net income every year, most notably in 2024. In 2025 operating cash flow was $9.958 billion and Capex was $1.858 billion; in 2024 operating cash flow was $11.490 billion and Capex was $1.096 billion. 【Opinion】This shows the company overall is not "manufacturing" profit through accruals but genuinely converts most of its profit into cash. Note that both 2024 and 2025 operating cash flow were affected by working-capital timing: the company explicitly states in its 10-K that the 2025 decline in operating cash flow was partly due to timing factors from higher Q4 2024 collections; at year-end 2025 accounts receivable rose from $6.782 billion to $9.570 billion, inventory fell from $6.998 billion to $6.225 billion, and accounts payable rose from $1.908 billion to $2.367 billion. This is not a sign of fraud, but it means one should normalize cash flow.
Whether growth requires large amounts of capital. 【Fact】The official historical financials page shows 2021-2025 capex of about $880 million, $940 million, $1.11 billion, $1.10 billion, and $1.86 billion, with capex intensity long running at roughly 3% to 5% of revenue; compared with many manufacturers, this is not heavy. But a drugmaker's true "capital expenditure" is not only plants but shows up as R&D and BD/M&A. In 2025 R&D had risen to $7.272 billion, of which late-stage clinical programs reached $4.281 billion, and management has explicitly said it will keep increasing late-stage clinical investment. 【Opinion】So Amgen is a light-on-tangible-capital, heavy-on-R&D-capital enterprise: expansion does not burn much on plants, but it continually burns brainpower, trials, and M&A funding.
Balance sheet, leverage, and survivability. 【Fact】As of year-end 2025, the company held cash of $9.129 billion, current portion of long-term debt of $4.599 billion, long-term debt of $50.005 billion, total assets of $90.586 billion, and shareholders' equity of $8.658 billion. The official snapshot gives an FY Current Ratio of 1.14 and FY Total Debt/Equity of 630.68%. This means book equity is very thin, and the ROE reading is amplified by "thin equity" and should not be simply read as excellent operations. Even so, in 2025 the company's net debt/EBITDA fell back to about 2.7x, a clear improvement over 2023-2024, showing deleveraging is still underway. 【Opinion】This balance sheet is still manageable, but not "comfortable." For conservative-leaning investors, it is heavier than in 2021-2022 and more reliant on future cash-flow delivery than the most solid large drugmakers.
Accounting risk, signs of manipulation, and share-count changes. 【Fact】I have not seen hard evidence of obvious financial fraud or aggressive revenue pulling-forward: free cash flow has been consistently positive and higher than net income, 2025 stock-based compensation was about $494 million, share count stayed basically in the 538-542 million range from 2023 to 2025 with no excessive dilution; at the same time, there were no open-market buybacks in 2025, showing the company has not recently propped up per-share metrics artificially through large buybacks. What warrants caution is not revenue fraud but the distortion of GAAP profit from merger amortization, asset impairments, and fair-value swings in equity investments, and how such accounting noise may cause investors to over- or under-estimate true earnings power.
Owner-earnings analysis. 【Fact】From a Buffett-style "owner earnings" angle, I prefer to start from operating cash flow rather than net income. In 2025 operating cash flow was $9.958 billion and Capex was $1.858 billion; given that the company's 2021-2024 Capex mostly fell in the roughly $880 million to $1.11 billion range, while 2025 Capex included new-plant and capacity-expansion factors, I consider it reasonable to conservatively estimate maintenance capex at about $1.2 billion 【Assumption】. On that basis, 2025 conservative Owner Earnings ≈ 9.958 - 1.20 = $8.76 billion. If one further accounts for 2025 operating cash flow being depressed by accounts-receivable and collection timing, then normalized owner earnings most likely fall in the $8.8 billion to $9.5 billion range.
Owner Earnings versus net income. 【Opinion】This company's long-term true earning power is closer to free cash flow/owner earnings than to GAAP net income. On a conservative basis of $8.76 billion against a current market cap of about $180.37 billion, the current share price implies about 20.6x conservative owner earnings; on the $8.8-9.5 billion normalized owner-earnings range, it is about 19-20.5x. This is not an outrageous valuation, but it is by no means the bargain price a value investor dreams of.
Valuation and Margin of Safety
Method 1: owner-earnings discounted cash flow. All valuations below are 【Calculation】 and 【Assumption】, not fact. I use 2025 conservative/normalized owner earnings as the starting point, use year-end net debt of about $45.48 billion as the debt adjustment, and adopt a 5-10-year long-term-owner view rather than a one-year EPS view. The raw inputs come from Amgen's cash flow, debt, and current market cap/share price.
| Scenario | Starting owner earnings | First-decade growth | Discount rate | Terminal growth | Est. intrinsic value/share |
|---|---|---|---|---|---|
| Conservative | $8.5 billion | 2% | 9% | 2% | ~$145 |
| Base | $8.9 billion | 4% | 8.5% | 2.5% | ~$230-235 |
| Optimistic | $9.3-9.5 billion | 5%-5.5% | 8% | 3% | ~$340-350 |
Explaining this DCF. 【Opinion】This DCF's conclusion is on the conservative side, but it captures the key reality: Amgen is neither a zero-growth utility stock nor a high-certainty, high-growth consumer name. It has real cash flow and new products, and it also has mature-product erosion and policy price pressure, so the discount rate cannot be too low and the terminal growth rate should not be set too high. On pure DCF, the current price of $331.57 has already discounted in quite a few optimistic scenarios.
Method 2: relative valuation. 【Fact】AMGN's current P/E is about 23.1x; the official Snapshot gives Price/Sales TTM of about 4.81x, Price to Cash Flow TTM of about 14.07x, and Price/Book FY of about 20.63x. Using 2025 data for my own calculation, Amgen's current P/FCF is about 22.3x and EV/EBITDA about 13.4x. On a cross-sectional basis, BMS P/E is about 16.4x, Regeneron about 15.9x, Merck about 31.8x, Eli Lilly about 36.2x, while AbbVie's current raw P/E is about 104.6x, distorted by GAAP conventions and not suitable for mechanical comparison. 【Opinion】This means Amgen sits in the position of "not cheap among mature large drugmakers, not expensive among growth large drugmakers"; if you treat it as a defensive asset, it is not cheap; if you treat it as a growth stock, it is not fast enough. P/B is even less meaningful, because the company's book equity is too thin and intangibles too heavy.
Method 3: asset or liquidation value. 【Fact】At year-end 2025 Amgen had cash of $9.129 billion on the books, total long-term debt of about $54.604 billion, goodwill of $18.680 billion, net intangible assets of $22.276 billion, while shareholders' equity was only $8.658 billion. In other words, goodwill + intangible assets together exceed $40 billion, far above book net assets. On a "tangible net worth" basis, Amgen's tangible net assets are actually negative, showing book value cannot provide a strong floor of protection for shareholders. 【Opinion】Therefore, this company is not suited to supporting a purchase on liquidation value; its value rests almost entirely on future drug cash flows, not on realizable assets. For conservative investors, this precisely requires the entry price to be stricter.
My composite intrinsic-value judgment. 【Opinion】On conservative DCF alone, the current price is expensive; adding relative valuation and the large-drugmaker "high-quality cash-flow premium," the reasonable range can be revised slightly upward, but it is still hard to conclude it is "clearly cheap." My composite ranges are as follows:
Conservative intrinsic-value range: $200-250/share
Fair intrinsic-value range: $260-320/share
Optimistic intrinsic-value range: $320-380/share
At the current roughly $331.57, it sits broadly at the upper edge of the fair range to the lower edge of the optimistic range, closer to a "hold price" than an "ideal buy price."
Actionable ranges. 【Opinion】
Ideal buy-price range: $240-280. This range corresponds roughly to 14-17x conservative Owner Earnings and can provide a cushion of about 20%.
Acceptable hold-price range: $280-340. The price is not low, but if you already own it, the business quality is enough to justify continued watching.
Clearly overvalued price range: above $380. That usually means the market has assigned too high a probability of growth/pipeline success.
Margin-of-safety judgment. 【Opinion】The margin of safety at the current price is insufficient. The most fragile assumption in the valuation is not "whether the company will die" but "whether new products and the pipeline can fill the gap left by aging products and policy erosion fast enough." If Repatha, EVENITY, BLINCYTO, TEPEZZA/KRYSTEXXA, TEZSPIRE, and the follow-on pipeline cannot keep delivering, and the market pushes the valuation back to the level of a more ordinary mature drugmaker, then even if the company keeps making money, shareholders' annualized returns could be quite ordinary. In other words, the biggest risk here is: a good company, but a bad price.
Risks, Comparison, and Final Checklist
The most important risks. 【Fact】Competitive risk is already very concrete: the RANKL-antibody patents for Prolia/XGEVA expired in 2025, and the company itself expects competitive erosion to accelerate in 2026; ENBREL sales already fell 33% year over year in 2025 and still face IRA drug-price negotiation and state-level ceiling payments; Otezla has also been selected by CMS for subsequent price setting. Technology-substitution risk shows up in follow-on products having to replace the profit pool of older products, not merely bring "nice-looking" sales growth. Financial-leverage risk, though mitigated, has not vanished; if management does another large debt-driven acquisition, it will raise the risk again. Supply-chain and accounting risks are not the main contradiction, but complex taxes, intangible-asset impairments, and fair-value swings in equity investments could all make GAAP statements look very ugly in the short term.
The strongest counterargument. 【Opinion】The strongest bear case is actually simple: Amgen is not "continuously widening its moat" but "using new products and M&A to fill the holes as the old moat narrows." If you accept this premise, then the current roughly 23x P/E and roughly 22x FCF price is no longer cheap, because it looks more like paying a high-quality premium for "rolling maintenance" than buying an asset that can compound fast at a low price. The bears would say: the strong 2025 performance masks two facts: first, growth largely comes from the earlier large acquisition and new-product handoffs; second, policy and patent-expiry risks are not one-off but persist for years to come. I do not consider this counterargument weak.
What facts would overturn my investment judgment. If the following occur, I would admit my judgment of its "long-term value" needs to be revised down, even turned negative:
The combined incremental contribution of Repatha, EVENITY, BLINCYTO, TEZSPIRE, and TEPEZZA/KRYSTEXXA in 2026-2027 fails to cover the profit loss from Prolia/XGEVA, ENBREL, and Otezla.
Net debt/EBITDA stays above about 3x and deleveraging stalls.
MariTide, IMDELLTRA, or a key late-stage program fails, leaving no adequate new engine for the next two to three years.
Management launches another large, highly leveraged acquisition, prioritizing it over continued debt reduction.
IRA, state-level drug-price ceilings, 340B, and other policies expand to more core products.
Comparison with other opportunities. 【Opinion】Comparing it with the "strongest opportunities in the same industry" and with indices and Treasuries: Versus Lilly and similar high-growth large drugmakers, Amgen is clearly more mature and more defensive but grows far more slowly; versus BMS/Regeneron and similar lower-valued mature drugmakers, Amgen's business is more balanced and its dividend path better, but its price is also higher. Versus the 10-year Treasury at about 4.50%, Amgen's certainty edge after buying at the current price is not large; you need to believe in its future growth and pipeline delivery to earn reasonable risk compensation. Versus the S&P 500, I do not think Amgen at the current price has a "clearly better than buying the index" edge; it is more like a defensive, cash-flow, healthcare-allocation position than the core position in the portfolio most worth tying up capital in. If I could hold only 5 assets, Amgen at the current price would not necessarily make the cut; if the share price returned to the $240-280 range, its qualification to enter the portfolio would improve markedly.
Investment Checklist. The table below gives my conclusions from a long-term business-owner logic. In the table, "which key facts would make me sell" and "whether I am driven by emotion" are essentially self-discipline clauses, not financial metrics.
| Item | Conclusion | Brief |
|---|---|---|
| Can I understand this business | Pass | Top-level business logic is clear; the underlying is specialized but understandable |
| Does it have long-term stable demand | Pass | Disease demand is stable, but the product lifecycle is not |
| Does it have a durable moat | Pass | But overall stable-to-narrowing, not ever-widening |
| Does it have pricing power | Uncertain | Stronger for new/rare-disease products, weaker for mature Medicare products |
| Can it generate stable free cash flow | Pass | Consistent high-quality FCF from 2021 to 2025 |
| Is its return on capital excellent | Pass | But below its best years, and it fell back after the acquisition |
| Is management trustworthy | Pass | Governance and ownership are decent, transparency of communication fairly high |
| Is capital allocation rational | Uncertain | Recent debt reduction is a plus; Horizon still needs time to prove out |
| Is the balance sheet solid | Uncertain | Cash flow is manageable, but debt is heavy, equity thin, tangible net worth weak |
| Is the valuation below intrinsic value | Fail | Currently more like a fair-to-expensive price |
| Is the margin of safety sufficient | Fail | Risk compensation is not thick |
| Does long-term holding let me rest easy | Uncertain | The business is reassuring, the price is not |
| Which key facts would make me sell | Pass | See "signals that trigger reassessment" above |
| Am I buying only because of price or emotion | Uncertain | Currently more tempted by a "quality premium" than drawn by cheapness |
Final investment conclusion.
【Final Rating】 Watch
【One-Sentence Investment Thesis】 Amgen is a high-quality, cash-flow-solid mature biopharma company, but under the realities of a patent cliff, Medicare price pressure, and a heavier post-merger balance sheet, the current share price does not leave a sufficient margin of safety for long-term, conservative investors.
【Core Bull Case】
The product portfolio is more diversified than a single-product biotech; in 2025, 14 products had sales above $1 billion, with broad revenue sources.
Free-cash-flow quality is high; from 2021 to 2025 FCF was consistently higher than net income, and cash profit is real.
In 2024-2025 management prioritized debt reduction over aggressive buybacks, which is friendlier to conservative-leaning shareholders.
The growth mix combining old and new (Repatha, EVENITY, BLINCYTO, TEPEZZA, KRYSTEXXA, TEZSPIRE) is enough to keep the company from stalling due to a single product's decline.
R&D was clearly strengthened in 2025 with a large increase in late-stage clinical investment, showing the company is still betting on the next product cycle.
【Core Bear Case】
Prolia/XGEVA patents have expired, and the company itself expects erosion to accelerate in 2026.
ENBREL has declined significantly, and ENBREL/Otezla still face IRA drug-price setting.
The Horizon acquisition raised the debt and intangible-asset ratios, and liquidation-value support is weak.
The current valuation is not low, and the risk compensation shareholders receive relative to the 10-year Treasury is not generous.
Performance incentives shifted from non-GAAP ROIC to relative TSR, slightly weakening the long-term capital-allocation constraint.
【Key Assumptions】
Repatha, EVENITY, BLINCYTO, TEZSPIRE, and the rare-disease portfolio can keep growing.
The declines of Prolia/XGEVA and ENBREL/Otezla will not be faster than the market's most pessimistic expectations.
Management maintains the deleveraging pace and does not do new large, highly leveraged acquisitions.
MariTide, IMDELLTRA, and other late-stage programs at least partly deliver, able to take over future increments.
IRA and state-level drug-price controls do not quickly expand to more core growth products.
【Fair Buy Price】 $240-280/share. The basis: this range corresponds roughly to 14-17x conservative Owner Earnings and can provide a more respectable buffer against patent expiry, policy changes, and post-merger deleveraging falling short of expectations.
【Target Holding Period】 At least 5-10 years; ideally viewed over a full product cycle and capital-allocation cycle rather than by quarterly EPS.
【Expected Annualized Return】 Estimated on buying at the current roughly $331.57 and holding 10 years:
Conservative scenario: 2%-4%
Base scenario: 5%-7%
Optimistic scenario: 8%-10% These returns are not bad, but for an equity asset carrying a biologic patent cliff and policy uncertainty, they are not especially enticing either.
【Maximum Loss Risk】 If the denosumab and ENBREL/Otezla profit pools decline faster than expected, Horizon returns fall short of cost, the pipeline fails to hand off, and the valuation falls back to the range of a more ordinary mature drugmaker, a 35%-50% permanent capital loss from the current level is not unimaginable. The worst case is not bankruptcy but long-term failure to compound.
【Tracking Metrics】
Repatha annual sales and price/volume breakdown
Prolia/XGEVA biosimilar erosion pace
ENBREL and Otezla net-selling-price changes under IRA/state-level policy
The rare-disease portfolio, especially the continued growth of TEPEZZA and KRYSTEXXA
The share of late-stage clinical programs in R&D spending
Net debt/EBITDA and annual debt repayment
The divergence between free cash flow and Owner Earnings
Total share-count changes and equity-incentive dilution
Key pipeline milestones for MariTide, IMDELLTRA, etc.
Whether another large debt-driven acquisition appears
【Signals That Trigger Reassessment】
Management lowers medium-to-long-term expectations for core growth brands
Net debt/EBITDA rises again and stays above 3x for a long time
The rare-disease portfolio misses expectations, shaking the Horizon deal logic
A key late-stage program fails
More core products are brought into price setting or state-level price caps
Free cash flow is persistently and significantly below net income and cannot be explained by working capital
【Final Recommendation】 Coolly put, Amgen is worth researching and worth tracking long-term, but may not be worth actively buying now. If you already own it, it is closer to an asset to "keep holding and track delivery closely"; if you have no position, I would rather wait for a thicker price discount and then own it in the manner of a long-term business owner. True value investing is not buying a good company, but buying a good company at a sufficiently conservative price.
This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.
Full report
Sign in to read the full report
Sign up free to unlock the full text, the Baillie growth scorecard, and full-text search.
Log in / Sign up free